1-9 of 9
Ju-Whei Lee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152

Neil Palmisiano, Ju-Whei Lee, David F. Claxton, Elisabeth Paietta, Hassan B. Alkhateeb, Jae H Park, Nikolai Podoltsev, Ehab L. Atallah, Dale G Schaar, Shira Dinner, Jonathan Webster, Selina M. Luger, Mark R. Litzow
Journal: Blood
Blood (2021) 138 (Supplement 1): 3407.
https://doi.org/10.1182/blood-2021-153621
Published: 2021
Journal Articles

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Clinical Trials & Observations
Simon Mantha, Debra A. Goldman, Sean M. Devlin, Ju-Whei Lee, Diana Zannino, Marnie Collins, Dan Douer, Harry J. Iland, Mark R. Litzow, Eytan M. Stein, Frederick R. Appelbaum, Richard A. Larson, Richard Stone, Bayard L. Powell, Susan Geyer, Kristina Laumann, Jacob M. Rowe, Harry Erba, Steven Coutre, Megan Othus, Jae H. Park, Peter H. Wiernik, Martin S. Tallman
Journal: Blood
Blood (2017) 129 (13): 1763–1767.
https://doi.org/10.1182/blood-2016-10-747170
Published: 2017
Journal Articles

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Clinical Trials & Observations
Marlise R. Luskin, Ju-Whei Lee, Hugo F. Fernandez, Omar Abdel-Wahab, John M. Bennett, Rhett P. Ketterling, Hillard M. Lazarus, Ross L. Levine, Mark R. Litzow, Elisabeth M. Paietta, Jay P. Patel, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Zhuoxin Sun, Selina M. Luger
Journal: Blood
Blood (2016) 127 (12): 1551–1558.
https://doi.org/10.1182/blood-2015-07-657403
Published: 2016
Includes: Supplemental data
Journal Articles

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F. Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD
Journal: Blood
Blood (2014) 124 (21): 2599.
https://doi.org/10.1182/blood.V124.21.2599.2599
Published: 2014
Journal Articles

Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia

Muhamed Baljevic, MD, Bogdan Dumitriu, MD, Ju-Whei Lee, PhD, Elisabeth Paietta, PhD, Janis Racevskis, Christina Chen, BS, Eytan M. Stein, Robert E Gallagher, MD, Jacob M. Rowe, MD, Frederick R. Appelbaum, MD, Bayard L. Powell, MD, Richard A. Larson, Neal S. Young, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2014) 124 (21): 2375.
https://doi.org/10.1182/blood.V124.21.2375.2375
Published: 2014
Journal Articles

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Elisabeth M. Paietta, PhD, Janis Racevskis, PhD, Hugo F Fernandez, MD, Ju-Whei Lee, PhD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Jay P. Patel, Mithat Gönen, PhD, Omar Abdel-Wahab, MD, Ross L Levine, MD, Elihu H. Estey, MD
Journal: Blood
Blood (2014) 124 (21): 941.
https://doi.org/10.1182/blood.V124.21.941.941
Published: 2014
Journal Articles

Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era

Simon Mantha, MD MPH, Debra Goldman, MS, Sean M. Devlin, PhD, Ju-Whei Lee, PhD, Diana Zannino, BSc, MSc, Dan Douer, MD, Harry J Iland, MBBS FRACP FRCPA, Mark R. Litzow, MD, Eytan M. Stein, Frederick Appelbaum, MD, Richard A. Larson, Jacob M. Rowe, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2014) 124 (21): 948.
https://doi.org/10.1182/blood.V124.21.948.948
Published: 2014
Journal Articles

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD
Journal: Blood
Blood (2014) 124 (21): 373.
https://doi.org/10.1182/blood.V124.21.373.373
Published: 2014
Journal Articles

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Chezi Ganzel, MD, Judith Manola, MS, Dan Douer, MD, Jacob M. Rowe, MD, Hugo F Fernandez, MD, Elisabeth Paietta, Ph.D, Mark R. Litzow, MD, Ju-Whei Lee, Selina M Luger, MD, Hillard M. Lazarus, MD, Larry Cripe, MD, Martin M Oken, MD, Peter A Cassileth, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2013) 122 (21): 63.
https://doi.org/10.1182/blood.V122.21.63.63
Published: 2013